Lin, Chih-Wen
Chen, Yaw-Sen
Lo, Gin-Ho
Wu, Tsung-Chin
Yeh, Jen-Hao
Yeh, Ming-Lun
Dai, Chia-Yen
Huang, Jee-Fu
Chuang, Wan-Long
Roberts, Lewis
Jun, Dae Won
Toyoda, Hidenori
Yasuda, Satoshi
Nguyen, Mindie H.
Yu, Ming-Lung http://orcid.org/0000-0001-8145-1900
Funding for this research was provided by:
Ministry of Science and Technology, Taiwan (105-2314-B-650-004-MY3, 108-2314-B-214-006-MY2)
E-Da Hospital-National Taiwan University Hospital Joint Research Program (108-EDN11, 109-EDN03)
E-Da Hospital (EDAHP109044, EDAHP109045, EDAHP109053, EDPJ105056, EDPJ106094, EDPJ107076, EDPJ1080696)
Kaohsiung Medical University Grant (KMU-DK109002, Research Center Grant, Cohort Research Center KMU-TC108B07, Center of Cancer Research KMU-TCA04-3)
Article History
Received: 19 November 2020
Accepted: 23 February 2021
First Online: 18 May 2021
Declarations
:
: Mindie H. Nguyen: Advisory Board and/or consultation: Exact Sciences, Bayer, Eisai, Laboratory of Advanced Medicine. Wan-Long Chuang: Consultation: AbbVie, Bristol-Myers Squibb Merck, PharmaEssentia. Ming-Lung Yu: Research grant from Abbott, BMS, Gilead and Merck; onsultant of Abbvie, Abbott, Ascletis, BMS, Gilead, Merck and Roche; Speaker of Abbvie, Abbott, BMS, Gilead, Merck, and IPSEN. Hidenori Toyoda: Speaker of AbbVie and Gilead. Other authors have no conflicts to declare.
: This study was approved by the Institutional Review Board at each participating institution.
: Informed consent was not required in this study.